NICE's response to comments on the draft scope and provisional stakeholder list (PDF 238 KB) Published: 09 March 2026
Following discussions with the company, this appraisal has been combined with ID6301. The combined appraisal will continue under ID6607, and the new title is "Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer".